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Summary 
Recent studies  have shown  that  only a  subset  of major histocompatibility complex (MHC) 
class II molecules are able to present bacterial superantigens to T  cells, leading to the suggestion 
that  class II-associated peptides may influence  superantigen  presentation.  Here, we have as- 
sessed the potential role of peptides on superantigen presentation by (a) analyzing the ability of 
superantigens to block peptide-specific T  cell responses and (b) analyzing the ability of individ- 
ual  peptides  to  promote  superantigen  presentation  on  I-Ab-expressing T2  cells  that  have  a 
quantitative defect in antigen processing. A series of peptides is described that specifically pro- 
mote either toxic shock syndrome toxin (TSST) 1 or staphylococcal enterotoxin A  (SEA)  pre- 
sentation. Whereas some peptides promoted the presentation of TSST-1  (almost 5,000-fold in 
the case of one peptide), other peptides promoted the presentation of SEA. These data demon- 
strate that MHC class II-associated peptides differentially influence the presentation of bacterial 
superantigens to T  cells. 
B 
acterial superantigens are toxins that are characterized 
by their ability to polyclonally activate T  cells express- 
ing certain V[3 elements of the TCIk (1, 2). This activity is 
mediated by direct binding  of the  superantigen  to  MHC 
class II molecules and the VI3 element of the TCK, result- 
ing in the formation of a trimolecular complex (3). In con- 
trast to conventional antigen presentation by MHC class II 
molecules, superantigens bind to regions of class II outside 
the peptide-binding groove, and there is no requirement for 
antigen  processing  (1,  2,  4).  Thus,  T  cell  recognition  of 
bacterial superantigens is not classically  MHC restricted, al- 
though isotypic and allelic  differences in class II molecules 
influence superantigen  presentation  (5-8).  Recently,  crys- 
tallographic studies have detailed the association of two bac- 
terial superantigens, toxic shock syndrome toxin (TSST) 1 1 
and staphylococcal enterotoxin B  (SEB), with DR1  mole- 
cules  (9-12).  Both superantigens were bound to the same 
region of the DR1 o~ chain, although the modes of interac- 
tion were very distinct. However, several groups have shown 
that TSST-1 and SEB do not compete with each other for 
binding to DR1  molecules, even though the binding sites 
of TSST-1  and  SEB  overlap  almost  completely  (13-15). 
1Abbreviations used in this paper: CLIP, Class II-associated  invariant chain 
peptide; HEL, hen egg lysozyme; HN, hemagglutinin-neuraminidase; 
M, matrix; MCC, moth cytochrome C; SEA, SEB, staphylococcal en- 
terotoxin A and B, respectively;  TSST, toxic shock syndrome  toxin. 
These data suggested that TSST-1 and SEB are only able to 
bind to a subset of available DR1  molecules,  a possibility 
supported by direct binding studies  (15).  Interestingly, the 
crystal structure  of the  TSST-1-DR1  complex suggested 
that  there  might be  direct  contact  between  TSST-1  and 
DRl-bound  peptide  such  that  TSST-1  binding  may be 
peptide  dependent  (12).  Thus,  these  data  suggested  that 
MHC class II-associated peptides may define subsets of class 
II molecules that differ in their ability to present bacterial 
superantigens  to T  cells.  Here, we  assess the  influence  of 
peptides  on  the  presentation  of several bacterial superan- 
tigens. 
Materials and Methods 
Cell Lines.  The SEB121_136-specific hybridoma,  1732, will be 
described  in  detail  elsewhere  (Wen,  R.,  M.A.  Blackman,  and 
D.L.  Woodland,  manuscript  in  preparation).  Briefly,  C57B1/6 
mice were immunized in the base of the tail with heat-inactivated 
SEB emulsified in complete Freund's  adjuvant. T cells were sub- 
sequendy  activated in vitro with inactivated  SEB and fused with 
the BW5147ot-[3-  fusion partner.  1732 was one of a series ofhy- 
bridomas  that specifically responded  to inactivated  SEB on live, 
but not fixed, I-Ab-presenting cells. A panel of overlapping  16- 
mer peptides encompassing the entire SEB protein synthesized by 
Chiron Mimotopes (Clayton,  Australia) was used to determine 
that 1732 recognized  SEB121_136. Specificity was confirmed using 
peptide that was resynthesized by the Molecular Resource Center 
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1732  recognizes SEB121_136 in the context of I-A  b, but not I-A  a, 
I-A  k, l-Aq, I-AP, I-E  d, or I-E  k (data not presented). Hybridomas 
specific for Sendal virus hemagglutinin-neuraminidase (HN), Sen- 
dai virus man-ix  (M),  moth cytochrome c  (MCC),  and hen  egg 
lysozyme (HEL) peptides have been previously described (16--19). 
SEB-specific hybridomas 603 and 610 have been described previ- 
ously (20-22). Hybridomas B3.3F6 and 1732  are staphylococcal 
enterotoxin A (SEA) reactive and B3.2H3 and 1826 are TSST-1 
reactive (Wen,  IL.,  and  D.L.  Woodland, unpublished data).  A 
further  six  SEA-specific and  nine  TSST-l-specific hybridomas 
were  also  tested in  this study. These  hybridomas were derived 
from fusions of SEA- or TSST-l-acdvated T cells and will be de- 
scribed elsewhere (Wen P,.,  M.A. Blackman, and D.L. Wood- 
land,  manuscript in  preparation).  I-A  b- and  I-Ek-transfected L 
cells (FT 7.1C6  and DCEK Hi7)  (23)  were a gift from Dr.  R. 
Germain  (National Institutes of Health,  Bethesda,  MD).  I-A  k- 
transfected L cells have been described elsewhere (21). 
Peptides.  All of the peptides used in this study, with the excep- 
tion of Sendal virus HN41s-430 and SEB121q36, have been previously 
described (16-19, 24). Both HN41s.430 (GDR_VYIYTR.SSGWHSP) 
and SEB121_136 (HNGNQLDKYP,.SITVILV) will be described in 
separate studies  (Cole,  G.A., T.L.  Hogg,  and D.L.  Woodland, 
manuscript in preparation; Wen, [L., et al., manuscript in prepara- 
tion). All of the peptides were synthesized either by the Molecular 
ILesource  Center  (HN418_433, HN421_436, HN559.574, M147_162, 
M33t_346, SEB121_136, HEL46_t6, MCC88_103) or by Chiron Mimo- 
topes (HN163.178, HN199_215, HN205_221, HN415_430, HN475.490). 
Superantigen-binding Assays.  SEA and TSST-1 binding was deter- 
mined as follows. T2-I-A  b cells were pulsed for 18 h with either 
HN421_436, SEB121_136, or left unpulsed at 37~  Cells were then 
incubated for 2 h with or without various doses of either SEA or 
TSST-1. Loaded cells were then stained with either rabbit anti- 
SEA or rabbit anti-TSST-1 antiserum (Toxin Technology, Sara- 
sota, FL) and FITC-labeled goat anti-rabbit secondary antibodies 
(Jackson  ImmunolLesearch Laboratories, Inc., West Grove, PA). 
Binding was assessed by flow cytometry using a FACScan  |  (Bec- 
ton Dickinson &  Co., Mountain View, CA). I-Ab-L cells were 
used as positive controls and showed strong binding of both su- 
perantigens. Background levels of staining were  determined by 
omitting the superantigen from the experiment. SEA, SEB,  and 
TSST-1 were all purchased from Toxin Technology. 
Superantigen-blocking Assays.  10  s APC (L cells transfected with 
either I-A  b, I-A  ~, or I-E  k genes) were incubated for 2  h  in the 
presence of a predetermined concentration of peptide before the 
addition of titered amounts of superantigen and 10  s peptide-spe- 
cific hybridoma cells in a final volume of 250 ~1 medium. After 
24 h,  IL-2 secretion was measured by standard IL-2 assay using 
the IL-2-dependent cell line HT-2 as described previously (21). 
1 U  of human  rIL-2 is  equivalent to  160  U  in  our assay. The 
concentration of peptide used in these studies was selected to in- 
duce suboptimal stimulation of the hybridomas (usually between 
40  and  320  IL-2  U/m1),  as  determined from  a  dose-response 
curve (see Table 1 for peptide concentrations). In some experi- 
ments, the conditions were altered such that peptide doses were 
used that induced a maximal IL-2 response from the hybridomas. 
In other experiments, the peptide preincubation period was ex- 
tended to  12 h  or the superantigen was added 2 or 12 h before 
the addition of the peptide and hybridoma cells. These conditions 
all yielded the same patterns of responsiveness, although blocking 
was less apparent at peptide doses that gave maximal stimulation 
of the hybridomas. In all experiments, appropriate MHC class II 
(M5/114.7,  10.3.6, and 14.4.4s,  anti-I-A  b, -I-A  k, and-I-E  k, re- 
spectively)- and  MHC  class  I  (11.4.1,  anti-Kk)-specific mAbs 
were  included to  confirm the ability of each hybridoma to  be 
blocked in this type of assay. To test the ability of SEB to block 
the response of the SEB~21_136-specific  hybridoma 1732 (described 
above), the I-Ab-L cells were fixed with 1% paraformaldehyde for 
30 min at room temperature to prevent processing of the SEB 
into stimulatory peptide. 
Superantigen Presentation Assays.  5 X 104 T2-I-A  b cells, TI-I-A  b 
cells (both gifts from Dr.  N.  Braunstein,  Columbia University, 
New York) or I-Ab-transfected L cells (FT 7.1C6, a gift from Dr. 
Ik. Germain) were incubated for 18 h at 37~  in the presence of 
100  p~g/ml  of indicated peptides before the  addition of titered 
amounts  of the appropriate superantigen and  105  superantigen- 
specific hybridoma cells.  IL-2 secretion was measured after 24 h 
as described above. In some experiments, the T2-I-A  b cells were 
preincubated with graded doses ofpeptide before the addition of 
a single suboptimal concentration of either SEA (0.02 p,g/ml) or 
TSST-1 (0.1 p,g/ml). In this case, the concentration ofsuperanti- 
gen was selected to maximize the window of IL-2 secretion be- 
tween the presence and absence ofsuperantigen. The background 
levels of IL-2 in these experiments reflects the ability of T2-I-A  b 
cells to present these concentrations of superantigen in the ab- 
sence ofpeptide. In all experiments, the level ofI-A  b on the sur- 
face of peptide-pulsed T2-I-A  b cells was determined by flow cy- 
tometry using the Y3P mAb (PharMingen, San Diego, CA). The 
pulsing ofT2-I-A  b cells with peptides did not affect I-A  b levels. 
Results 
Superantigens  Block  T  Cells Responses  to Conventional Pep- 
tide Antigens.  To investigate the role ofpeptides in super- 
antigen activity, we took advantage of the observation that 
bacterial superantigens  block the  presentation  of conven- 
tional peptides to T  cells (25, 26). We reasoned that super- 
antigens would not be able to block the T  cell response to 
peptides that did not promote superantigen binding. Thus, 
we assessed the ability ofTSST-1,  SEB, and SEA to block 
the  response  of a  panel of T  cell hybridomas to  conven- 
tional peptide antigens.  Fig.  1  shows  the  response  of five 
hybridomas  to  I-Ab-restricted peptides  derived  from  the 
Sendal virus hemagglutinin (HN421_436, HN163_178, HN415_430, 
HN205_221, HN418_433) (16)  and SEB  (SEB121_136) (Wen R., 
et al., manuscript in preparation) in the presence of titered 
amounts of superantigen. In each case, the presenting cells 
were L cells transfected with I-A  b (23) and the hybridomas 
analyzed were  all  unreactive  to  the  superantigens  studied 
(with the exception of hybridoma 1732,  which is SEA re- 
active). None of the peptide-specific responses tested were 
blocked by SEB. However, the responses of these hybrido- 
mas  were  differentially affected by SEA and TSST-1.  For 
example,  the  response  of hybridoma B3.4F3  to  HN421_436 
(Fig.  1  A)  was  completely blocked  by  SEA,  but  not  by 
TSST-1, whereas the response of B3.4D6 to HN163_178 (Fig. 
1 B) was blocked by TSST-1, but not by SEA. In contrast, 
the  response  of  B3.2G9  to  HN415_430  (Fig.  1  C)  was 
blocked by both SEA and TSST-1, whereas the response of 
B3.2A8  to HN205_221 was blocked by neither superantigen 
(Fig. 1 D). In each case, the ability ofsuperantigen to block 
the peptide-specific response was most apparent at subopti- 
mal concentrations of peptide. At higher peptide concen- 
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(data not shown). However, in one case, the recognition of 
S]EB121_136 by  hybridoma  1732  was  extremely  sensitive  to 
blocking by TSST-1, and this was also apparent at high pep- 
tide  doses  that  induce  maximal  responses  from  the  1732 
hybridoma  (Fig.  1  E).  In  the  representative  data  shown, 
peptide was added to the presenting cells 2 h before the ad- 
dition of graded doses of superantigen  and the appropriate 
hybridoma. Reversing the order of peptide  and superanti- 
gen addition and/or extending the period ofprepnlse to 12 h 
did not alter the patterns  of inhibition  described (data not 
shown). 
Altogether,  we  assessed  the  ability  of SEA,  SEB,  and 
TSST-1 to block 13 peptide-specific responses (summarized 
in Table 1).  SEB did not inhibit the response of any of the 
hybridomas to their respective epitopes. However, SEA and 
TSST-1  gave distinct patterns  of inhibition  to each of the 
peptides,  and these  patterns  appeared to be peptide  rather 
than hybridoma specific. For example, even though several 
of the peptides were recognized by two or three distinct hy- 
bridomas, the pattern of inhibition was always the same for 
a given peptide. Interestingly, peptides that differed from each 
other by only three amino acids at the NH2 and COOH  ter- 
mini gave different patterns  of blocking.  For example,  the 
response of B3.2G9 to HN415_430 was blocked by both SEA 
and TSST-1, whereas the response of the same hybridoma 
to HN418_433 was only blocked by SEA (Table  1 and Fig. 1, 
C  and F). It has been shown that amino acids flanking the 
MHC-binding  core of the peptide  can influence  recogni- 
tion by T  cells (27). Thus, it is not dear whether this find- 
ing represents differences in the affinity of the B3.2G9 TCR 
for these two peptides or whether these two peptide-MHC 
complexes differentially interact with TSST-1. 
Peptides Influence the Presentation of Superantigens to  T  Cells. 
It is clear that the  ability of superantigens  to block a pep- 
tide-specific response ~  be influenced by many factors, in- 
cluding the relative affinities  of superantigen,  peptide,  and 
TCR for the class II molecule. However, the reciprocal pat- 
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Figure  1.  Bacterial superantigem differen- 
tially inhibit peptide-specific T cells. Five hy- 
bridomas--B3.4F3  (A), B3.4D6 (B), B3.2G9 
(C and F), B3.2A8 (D), and 1732 (E)--were 
tested for their ability to respond to suboptimal 
doses of their respective peptide antigens in the 
presence of titered amounts of SEA (0), SEB 
(ll  L and TSST-1 (A). The doses of peptide 
used for these experiments are detailed in Table 
1 and stimulated the hybridomas to secrete be- 
tween 40 and 320 U/ml of IL-2, which is rep- 
resented as 100% response. The actual amounts 
of IL-2 secreted by each of the  hybridomas 
were 40 U/ml (C'), 80 U/ml (D and E), 160 U/ 
ml (A and B), and 320 U/ml (F). Maximal IL-2 
secretion by these hybridomas  is normally either 
1,280 or 2,560 U/ml. SEA inhibition data for 
hybridoma 1732 is  not available because this 
hybridoma is SEA reactive. Each panel is repre- 
sentative of at least three independent experi- 
ments. 
1085  Wen et al, Table 1.  Bacterial  Superantigens Inhibit the T Cell Response to Peptide Antigens Presented by MHC Class II Molecules 
Inhibition* 
Peptide  Concentration*  Hybridoma  V[3~  SEB  SEA  TSST-  1 
I,*g/ml 
HN163_I78  0.05  B3.4D6  6  -  -  + 
HN199-21s  2.0  B3.2A8  5.1  -  -  + 
HN20s_221  0.4  B3.2A8  5.1  -  -  - 
HN415_430  4.0  B3.4F3  2  -  +  + 
4.0  B3.2G9  16  -  +  + 
HN418_433  2.0  B3.4F3  2  -  +  - 
2.0  B3.2G9  16  -  +  - 
0.04  B3.2G4  16  -  +  - 
HN421_436  0.8  B3.4F3  2  --  +  -- 
0.1  B3.2G4  16  -  +  - 
HN475_490  1.0  B3.8G2  6  --  +  + 
HNssg_574  0.025  B3.2H3  15  -  SIL  SR 
M147 162  1.6  B3.3F6  12  -  SR  + 
M331_346  0.04  B3.4D4  8.3  SR.  SP,  - 
SEB121-136  1.0  1732  1  -  II  SR  + 
HELa6_t,,1 (I-A  ~')  1.0  1C5.I.P3P  6  -  -  - 
2.0  3A9.2  8.2  SR  -  - 
MCC88-103 (l-Ek)  0.16  1397  8.1  SR.  +  - 
*+ and -  indicate the ability ofsuperantigens to block peptide-specific  responses (8). SR indicates that the hybridoma was superantigen  reactive, 
which precluded inhibition  studies. 
*The concentration of peptide used for the blocking study was a suboptimal dose determined from an independent dose-response  curve. 
~VI3 usage in the hybridomas was determined by flow cytometry and Northern blot analysis and has been detailed elsewhere (16, 27; Wen R., et al., 
manuscript in preparation). 
IISince hybridoma 1732 is able to respond to a processed peptide  derived from SEB, the ability of SEB to block SEB 121-136 recognition was deter- 
mined on fixed I-Ab-L cells (8). 
terns of blocking described here  cannot be fully explained 
in these terms and suggest that peptides are differentially af- 
fecting the ability of superantigens to block peptide-specific 
T  cells.  To  further  investigate this  hypothesis  we  assessed 
the effects of these peptides on the presentation ofsuperan- 
tigens  to  superantigen-reactive  hybridornas  using  T2  ceils 
that  have  been  transfected  with  I-A  b  (T2-I-A  b)  (28,  29). 
This cell line has a chromosomal deletion encompassing the 
DM genes, resulting in a quantitative defect in antigen pro- 
cessing such that most I-A  b molecules expressed on the cell 
surface  are  either  empty or associated with  class  II-associ- 
ated  invariant  chain-derived  peptides  (CLIP)  (30-33). 
Thus, these cells can be efficiently loaded with a single I-A  b- 
binding peptide.  T2-I-A  b cells were  loaded  overnight with 
I-Ab-specific peptides described in Table 1 and then tested 
for their ability to present SEA, SEB or TSST-1 to superan- 
tigen-specific hybridomas (Fig. 2). The SEB-specific hybri- 
domas tested with this assay responded only weaHy to SEB 
presented by T2-I-A  b (despite  the fact that  these hybrido- 
mas gave strong responses to SEB presented by I-Ab-trans  - 
fected L cells), and this response was not influenced by any 
of the  peptides  described  above.  However,  some  of the 
peptides had a strong effect on TSST-1  and SEA presenta- 
tion.  For  example,  SEB121_I36 enhanced the  ability of T2- 
I-A  b cells to stimulate two  TSST-l-specific hybridomas by 
almost 5,000-fold (Fig. 2, A  and B). The enhancement was 
not a generic effect, but was superantigen specific, because 
the same peptide did not enhance the presentation of SEA 
(Fig. 2,  C  and D). In contrast, HN421_436 enhanced the pre- 
sentation of SEA 9-fold (25-fold in some experiments) but 
had  a  minimal effect  on  TSST-1  presentation  (3-fold en- 
hancement) (Fig. 2,  C  and D). To confirm the generality of 
these observations, we assessed the effects of these peptides 
on superantigen presentation  to  a  further six SEA-specific 
and nine TSST-l-specific hybridomas. In all cases,  the in- 
fluence of peptides on superantigen presentation was iden- 
tical to that illustrated in Fig. 2  (data not shown). 
In other experiments, we assessed the response of the hy- 
bridomas to  a  single dose  of TSST-1  or SEA in the pres- 
ence of titered amounts ofpeptide. As shown in Fig. 3, the 
effect  of a  given peptide  on superantigen presentation was 
dose  dependent.  The differences in superantigen presenta- 
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Figure 2.  Peptides enhance the presentation of bacterial superantigen T2-I-A  b cells. TSST-l-specific hybridomas 1826 (A) and B3.2H3 (B) or SEA- 
specific hybridomas 1732 (C) and B3.3F6 (D) were tested for their ability to recognize TSST-1 (A and B) or SEA (C and D) presented by T2-I-A  b cells 
pulsed with M146_161  (O),  SEBt2I_I36  (Q), HN41s_433 (~), HNs5,~_574 (A), HN42t_436 (m), or left unpulsed (l-q). Since hybridomas B3.2H3, 1732 and B3.3F6 
specifically  recognize HN559_s74, SEB121_t36, and M146_161, respectively, these combinations of hybrid and peptide were not analyzed. Two strongly SEB- 
reactive hybridomas, 603 and 610, were also tested in this assay.  These hybridomas responded only weakly to SEB presented by T2-I-A  b (tested up to 100 
p,g/ml), and this response was not influenced by the presence or absence of the peptides described above (data not shown). Data are from a single assay 
that is representative of four independent experiments. 
tion were not controlled by peptide-specific effects on the 
absolute level of MHC  class II molecule expression, since 
peptide-loaded  T2-I-A  b  cells  expressed  similar  levels  of 
I-A  b  (within  a  twofold range)  as  determined by flow  cy- 
tometry.  Similarly, it is unlikely that these  effects are  due 
solely to  differences in  the  ability of peptides to  stabilize 
I-A  b molecules on T2-I-A  b cells because (a)  all but one of 
the peptides (M147_162) were strongly presented to the appro- 
priate peptide-specific hybridomas by T2-I-A  b cells (com- 
pared with  I-A  b L  cells, data not shown),  and  (b) peptides 
reciprocally influenced SEA and TSST-1 presentation. 
Correlation between Superantigen  Blocking  of Peptide-specific 
Responses and the Influence of Peptides on Superantigen Presenta- 
tion.  The ability of specific peptides to enhance superanfigen 
presentation by T2-I-A  b cells was generally consistent with 
the blocking studies (Fig. 1 and Table 1) inasmuch as peptide- 
enhanced superantigen presentation was associated with semi- 
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tivity  to  superantigen  blocking.  For  example,  SEBt21_136 
strongly enhanced  TSST-1  presentation by T2-I-A  b cells, 
and TSST-1  was also a  strong blocker of a  T  cell hybrid- 
oma specific for this  peptide.  Similarly, peptides that  en- 
hanced  SEA presentation by T2-I-A  b cells (HN418_433 and 
HN421_436) were also strongly blocked by SEA. One excep- 
tion to this correlation was the M147_162 peptide. Recogni- 
tion of this peptide was blocked by TSST-1, but the pep- 
tide did not significantly enhance  TSST-1  presentation by 
T2-I-A  b cells. It is possible that this peptide may not bind 
efficiently to T2-I-A  b cells, perhaps because of competition 
with CLIP peptides bound to I-A  b. In support of this, T2- 
LA  b cells were very poor presenters of this peptide to the 
M147_162-specific  hybridoma (compared with  I-Ab-L cells), 
whereas  all of the  other peptides were  strongly presented 
by T2-I-A  b cells to  the  appropriate hybridomas  (data not 
shown). ..~  !0000 
1000 
o 
o  100 
o 
r~ 
r 
10 
A  B 
10000 
100  10  1  0.1 
-t 
0 
1000 
100 
10  L_ 
, ........  i ........  g  ........  i  ""r'- 
100  10  1  0.1  0 
Peptide  concentration  (gg/ml) 
Figure 3.  Dose-response of  pep- 
tide-enhanced presentation of bac- 
terial  superantigens. A  TSST-1- 
specific hybridoma,  1826 (A), or 
SEA-specific  hybridoma, 1732 (B), 
were tested for their ability to rec- 
ognize  TSST-1  (A)  or  SEA  (B) 
presented by T2-I-A  b cells pulsed 
with  various  concentrations  of 
5EB121_136  (0),  HNss9_s74  (A),  or 
HN421_436  (m).  TSST-I  was 
present at 0.1 I.Lg/ml,  and SEA was 
present at 0.02 Ixg/mL These con- 
cent-rations of snperantigen  were 
chosen  to  optimize  the  effect of 
peptides on superantigen presenta- 
tion  for  the  titration.  The  back- 
ground secretion oflL-2 (20 U/ml 
in A and 80 U/rnl in/3) reflects  the 
abifity of T2-I-A  b cells to present 
these concentrations of superantigen in the absence of peptide (see Fig. 2). The SEB121_136 peptide titration was not done in B because hybridoma 1732 
specifically  recognizes this peptide. Data are from a single assay  that is representative of  three independent experiments. 
Presentation of Bacterial Superantigens by I-Ab-transfected L 
Cells.  Wild-type TI-I-A  b cells and I-AbL cells were po- 
tent presenters of SEA, SEB, and TSST-1 to T  cell hybrid- 
omas. Furthermore, superantigen presentation by these cell 
lines was not influenced by any of the peptides previously 
shown to affect superantigen presentation by T2-I-A  b cells. 
This suggests that some of the naturally processed peptides 
present on I-A  b molecules of these cells are potent enhanc- 
ers of superantigen presentation.  Interestingly, there was a 
distinct difference in the relative ability of T2-I-A  b cells and 
I-Ab-L cells to present these superantigens to T  cells. For 
example, SEA presentation by T2-I-A  b cells was  ~20-fold 
weaker than SEA presentation by I-Ab-L cells, and most of 
this deficit could be eliminated by the addition of appropri- 
ate peptides to the T2-I-A  b cells. In contrast, TSST-1 pre- 
sentation  by  T2-I-A  b  cells  was  >105  fold  weaker  than 
TSST-1  presentation by I-Ab-L cells. Pulsing I-Ab-L cells 
with  the  SEB121_136 peptide,  which  is  the  strongest  pro- 
moter of TSST-1  presentation, only restored presentation 
to ~1% of the level of I-Ab-L cells. These data suggest that 
there are peptides on I-Ab-L cells that are significantly more 
potent than  SEBt2H36  at promoting TSST-1  presentation. 
Furthermore,  the relatively strong ability of T2-I-A  b cells 
to present SEA suggests that this superantigen can function 
efficiently in the context of either empty I-A  b or NA  b mol- 
ecules that are associated with either CLIP peptide or other 
peptides that may be present in these cells. 
MHC-associated  Peptides Influence the  Binding  of SEA  to 
LA b.  One possible explanation for the ability of peptides 
to affect superantigen presentation to T  cells is that they di- 
rectly affect the binding of the superantigen to class II mol- 
ecules. To test this possibility, we measured SEA and TSST-1 
binding to T2-I-A  b cells in the presence or absence of dif- 
ferent  peptides  (Fig.  4).  For  these  studies,  we  focused  on 
peptides  that  specifically  enhanced  SEA  (HN421_436)  or 
TSST-1  (SEB121_136) presentation.  As  shown  in  Fig.  4  A, 
the  HN421_436 peptide strongly enhanced  SEA binding to 
T2-I-A  b  cells relative to  T2-I-A  b  cells alone  or  T2-I-A  b 
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Figure 4.  Peptides influence SEA, but not TSST-1, binding to NA  b. SEA binding (A) and TSST-I binding (/3) to SEBlzH36-1oaded  T2-I-A  b (12), 
HN421.436-1oaded T2-I-A  b (O), and T2-I-A  b in the absence ofpeptide (A) were determined by flow cytometry (as described in Materials  and Methods). C 
to I-A --transfected  L ceils.  Data are from a single  assay  that is representative  of  three independent experiments.  shows the binding of  SEA (0) and TSST-1 (11)  b 
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the fact that HN421_436, but not  SEB121_136, enhances SEA 
presentation to T cell hybridomas and suggest that peptides 
function by modulating the affinity of the SEA molecule 
for  I-A  b.  In  contrast,  neither  of the  peptides  tested  en- 
hanced the binding of TSST-1 to T2-I-A  b cells (Fig. 4 B), 
despite  that  fact  that  we  could  detect strong binding  of 
TSST-1 to I-Ab-transfected L cells (Fig. 4  C). It is possible 
that the ability of some peptides to enhance TSST-1 pre- 
sentation is  not mediated by an  effect on the binding of 
TSST-1  to  class II.  However,  it  should  be  noted  that 
SEB121_136-loaded T2-I-A  b cells are ,'~100-fold less efficient 
than I-A  b L cells at TSST-1 presentation to T  cell hybrido- 
mas. The binding assay may not be sensitive enough to de- 
tect  relatively weak  TSST-1  binding  to  SEB121_136-I-A  b 
complexes. 
Discussion 
The data presented here show that peptides  associated 
with MHC class II molecules are able to strongly influence 
the presentation of superantigens to T  cells.  For example, 
one  peptide,  SEB121_136, promoted  the  presentation  of 
TSST-1 by 5,000-fold, whereas  other peptides promoted 
SEA presentation. This phenomenon was clearly superanti- 
gen specific inasmuch  as peptides  that enhanced TSST-1 
presentation did not enhance SEA presentation,  and vice 
versa.  Thus,  these  data  indicate  that  the  mechanism  by 
which peptides influence the presentation of these two su- 
perantigens must be different. In this regard, it has recently 
been shown that SEA and TSST-1 bind to distinct regions 
of the MHC class II molecule (34, 35), potentially explain- 
ing the  differential effects of peptide,  as  discussed below. 
Interestingly, none of the peptides  tested influenced SEB 
presentation,  suggesting  that  peptides  do  not  affect  the 
binding of this superantigen to I-A  b. However, it should be 
noted that our assay systems may not be sensitive enough to 
detect peptide-specific effects because of the low affinity of 
SEB for I-A molecules in general (36).  Alternatively, it is 
possible that only rare peptides promote strong SEB pre- 
sentation by I-A  b, and peptides that induce very strong bind- 
ing of SEB are yet to be identified. Thus, the apparent low 
affinity of SEB for I-A  b (as measured in standard binding 
assays) may actually reflect the average of a small number of 
high-affinity interactions and a large number of  low-affinity 
interactions between I-Ab-peptide complexes and SEB. A 
theoretical extension of this  idea is  that  the  hierarchy of 
bacterial superantigen presentation is controlled, at least in 
part, by the array of peptides bound to specific class II iso- 
types and alleles  (5-8). This could also explain why differ- 
ent cell types expressing the same MHC class II molecules 
differ in their ability to present bacterial superantigens to T 
cells (37, 38). 
At least four possible mechanisms can be evoked to ex- 
plain the effect of peptide on the presentation of SEA and 
TSST-1. One possibility is that MHC class II-associated pep- 
tides induce conformational shifts in the superantigen that 
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enhance its ability to interact with the TCR VI3 element. 
Indeed, there is evidence to suggest that superantigens asso- 
ciated with class II molecules have a higher affinity for TCK 
(3).  However,  it  is  difficult  to  reconcile  this  hypothesis 
with the blocking studies presented here (Table 1 and Fig. 
1), since this assay is not dependent on TCl~--superantigen 
interactions. A second possibility is that individual peptides 
modulate T  cell recognition of superantigen by directly in- 
teracting with the TCR (21, 22, 39). This latter hypothesis 
seems unlikely becausse the crystallographic analysis of  TSST-1 
bound  to DRY appears  to be inconsistent with a  TCR- 
peptide interaction (12). In addition, this hypothesis would 
suggest that the ability of peptide to enhance superantigen 
presentation  would  be  TCR.  specific,  whereas  our  data 
show no evidence for such specificity. For example, several 
SEA- and TSST-l-reactive hybridomas all show the same 
response patterns to SEA and TSST-1 presented by T2-I-A  b 
loaded with different peptides (Fig. 2 and data not shown). 
A  third possibility is that superantigens may only bind to 
MHC class II molecules with an SDS-stable structure (26, 
40).  Thus,  superantigen presentation may depend  on the 
ability of individual peptides to stabilize  I-A  b molecules on 
T2-I-A  b cells. This capacity is known to vary between pep- 
tides  and  does  not  necessarily correlate with  antigenicity 
(41).  Because  individual  peptides  reciprocally  influence 
SEA and TSST-1 presentation, this stabilization cannot be 
a requirement for the presentation of both of these super- 
antigens. However, it remains a strong possibility for con- 
trolling the presentation of one of these superantigens. We 
are currently investigating the peptides described here for 
their ability to stabilize  I-A  b molecules with a view to cor- 
relating this  activity with  the  ability to promote SEA or 
TSST-1 presentation. A  fourth possibility is that the pep- 
tide alters the affinity of the superantigen--class  II interac- 
tion, either through direct contact between the peptide and 
the  superantigen  or  through  peptide-induced  conforma- 
tional changes in class II molecules. This hypothesis is con- 
sistent with the findings ofThibodeau et al. (15) that only a 
fraction of the available class II molecules on the cell sur- 
face are actually able to bind a given superantigen with high 
affinity. In support of this, our binding studies suggest that 
HN421_436 is able to significantly enhance SEA binding to 
T2-I-A  b, relative to T2-I-A  b loaded with SEB121_136 or no 
peptide.  Similar studies  by Kozono et  al.  (35)  have  also 
demonstrated that peptides bound to the class II-binding 
groove can influence the subsequent binding of SEA mole- 
cules.  In contrast to SEA, we have been unable to demon- 
strate enhanced binding of TSST-1 to T2-I-A  b cells loaded 
with  SEB121_136, which  is  a  potent promoter of TSST-1 
presentation. This was not a technical problem, because we 
could readily demonstrate  binding  of TSST-1  to  I-A  b L 
cells (Fig. 4 C). These data suggest that peptides may affect 
TSST-1  presentation  through  other mechanisms,  such  as 
conformational shifts in the TSST-1 molecule. However, it 
is  also  possible  that  the  failure  to  demonstrate  enhanced 
TSST-1 binding reflects limitations in the sensitivity of the 
binding  assay. In  this  respect,  it  should  be  noted  that 
SEB121_136-1oaded T2-I-A  b  cells  are  50--100-fold  weaker than I-Ab-L cells in terms of functional TSST-1  presenta- 
tion,  suggesting that TSST-1 binding to SEB121_136-pulsed 
T2-I-A  b cells is of comparatively low affinity. This contrasts 
with HNa21_a36-1oaded T2-I-A  b cells, which are almost equiv- 
alent to I-Ab-L cells in terms of  SEA presentation (not shown). 
The differential effects of peptide  on SEA and TSST-1 
presentation  can be readily accommodated in  a  model in 
which the superantigen directly contacts class lI-associated 
peptides, because SEA and TSST-1 bind to distinct regions 
of the  class II molecule. SEA has been shown to bind to 
two sites on class II, a high-affinity site at the  end of the 
peptide-binding groove and a low-affinity binding site on 
the class II ot chain  (34,  35).  Binding of SEA to the high- 
affinity site on class II could involve a direct interaction with 
the  NHz-terminal end of the  peptide.  For example, SEA 
binding might be controlled by the length  of peptide  ex- 
tending from the peptide-binding groove. In contrast, crys- 
tallographic analysis  of TSST-1  bound to DILl has shown 
that the superantigen binds  to the ot chain  of the  class  II 
molecule (12).  Interestingly, this structure suggests that the 
TSST-1  molecule potentially contacts the  COOH  termi- 
nus of the peptide in the peptide groove. Thus, the region 
of the peptide involved in SEA and TSST-1  presentation 
may be localized to opposite ends of the peptide.  Current 
studies are focused on identifying peptide residues involved 
in these different interactions.  It is interesting to note that 
T  cell responses to the HN415_430,  but not HN418_433, peptides 
were differentially blocked by TSST-1  (Fig.  1). This iden- 
tifies residues at either the NH  2 (415-417) or COOH  (431- 
433) termini of  the HN epitope that are able to affect TSST-I 
function (either by directly contacting TSST-1 or by altering 
the conformation of the peptide in the I-Ab-binding groove). 
The influence ofpeptides on SEA and TSST-1 presentation 
was significantly different in magnitude. Whereas TSST-1 
presentation could be enhanced several thousandfold,  SEA 
presentation could only be enhanced 10-20-fold. This dif- 
ference may reflect an important  divergence in the func- 
tion  of these  two  superantigens.  However,  only  a  small 
number of peptides have been tested  to date,  and further 
efforts may identify other peptides that have more dramatic 
effects  on  SEA  presentation.  Furthermore,  it  should  be 
noted that T2-I-A  b is a very strong presenter of SEA in the 
absence of peptide  (only 20-fold weaker than I-Ab--trans  - 
fected L cells).  This effectively reduces the range in which 
peptide-specific enhancement of SEA presentation can be 
observed. Thus, the 10--20-fold enhancement of SEA pre- 
sentation by the HN421-436 peptide (up to the level of I-Ab-L 
cells),  may represent maximal promotion of SEA presenta- 
tion. In this regard, the HN421_436  peptide may be more po- 
tent  at  enhancing  SEA  presentation  than  the  SEB121_136 
peptide  is  at  enhancing  TSST-1  presentation,  despite  the 
apparent potency of the latter peptide. Although SEBI21_136 
enhances TSST-1  presentation 5000-fold,  this is still  100- 
fold weaker than TSST-1  presented by I-Ab-L cells.  This 
possibility is  consistent with binding studies  showing that 
HN421.436 enhanced  SEA  binding,  whereas SEB12H36 en- 
hancement of TSST-1  could not be detected.  The differ- 
ence in the ability of TS-I-A  b to present SEA and TSST-1 
in  the  absence of peptides raises  the  possibility that  SEA, 
but not TSST-1,  is  able  to bind to  CLIP-associated I-A  b 
molecules that are relatively abundant on T2-I-A  b cells (29). 
In this case, one might expect to find peptides that displace 
CLIP but do not promote SEA presentation, resulting in an 
overall reduction in the ability of T2-I-A  b to present SEA. 
However,  reductions  were  not  observed with  any of the 
peptides tested. 
Taken together, the data presented here identify peptides 
that are able to influence the presentation of superantigens 
to  T  cells.  Since  normal APC  express  an  array  of MHC 
class II-bound peptides, it is possible that superantigens bind 
to APC with a range of affinities.  The overall avidity of su- 
perantigen recognition may influence  the  ultimate fate of 
superantigen-activated T  cells in terms ofapoptosis, anergy, 
or differentiation into memory cells. Clearly, this would af- 
fect the fate of potentially autoreactive T  cells that had been 
inadvertently activated by superantigen  exposure  and  po- 
tentially  have  an  impact  on  the  development of autoim- 
mune  disease  (42-47).  In addition,  the  influence  of pep- 
tides on superantigen presentation may have an impact on 
concurrent antigen-specific responses in vivo. For example, 
superantigens may divert the immune response to peptide 
antigens that do not promote superantigen binding. Clearly, 
the identification of specific peptides that are able to influ- 
ence  superantigen  activity  will  be  invaluable  for  under- 
standing the underlying mechanisms involved in superanti- 
gen presentation and have implications for the induction of 
autoimmune disease. 
We thank N. Braunstein for the generous gift ofT1, T2, TI-I-A  b, and T2-I-A  b cells, D. Vignali for provid- 
ing us with HEL-specific hybridomas and HEL peptide, and R. Gerrnain for providing us with L cells trans- 
fected with various class II molecules. We also thank A. Pu/len, N. Braunstein, and D. Vignali for both dis- 
cussions and critical reading of the manuscript, and 1L. Carson, J. Hurwitz, C. Coleclough, J. Mullersman, 
and M. Kotb for useful discussion. 
This work was supported by National Institutes of Health  grants CA-56570  and AI-31596 (D.L. Wood- 
land), AI-31489 (M.A. Blackman), and P30 CA-21765 (CORE), and the American Lebanese Syrian Associ- 
ated Charities. 
1090  Peptides  Control Bacterial Superantigen Presentation to T Cells Address correspondence to David L. Woodland, Department of Immunology, St. Jude Children's Research 
Hospital, 332 North Lauderdale, Memphis, TN 38105. 
Received for publication  19July  1995 and in revised  form 21 November 1995. 
References 
1.  Herman,  A., J.W.  Kappler,  P.  Marrack,  and A.M.  Pullen. 
1991. Superantigens: mechanism of T-cell stimulation and role 
in immune responses. Annu. Rev. Immunol. 9:745-772. 
2.  Marrack, P., andJ. Kappler. 1990. The staphylococcal entero- 
toxins and their relatives. Science (Wash. DC). 248:705--711. 
3.  Seth,  A.,  L.J.  Stern,  T.H.M.  Ottenhoff,  I.  Engel,  M.J. 
Owens, J.R.  Lamb, R.D.  Klausner, and D.C.  Wiley. 1994. 
Binary and ternary complexes between T-cell receptor class II 
MHC and superantigen in vitro. Nature (Lond.). 369:324-327. 
4.  Dellabona, P., J. Peccoud, J. Kappler, P. Marrack, C. Benoist, 
and D. Mathis. 1990.  Superantigens interact with MHC class 
II molecules outside of the antigen groove.  Cell, 62:1115- 
1121. 
5.  Fleischer, B., and H. Schrezenmeier. 1988.  T cell stimulation 
by staphylococcal enterotoxins. Clonally variable response and 
requirement  for  major  histocompatibility complex  class  II 
molecules on accessory or target cells._]. Exp. Med.  167:1697- 
1707. 
6.  Herrrnann,  T.,  R.S.  Accolla, and H.R.  MacDonald.  1989. 
Different staphylococcal enterotoxins bind preferentially to 
distinct major  histocompatibility complex class  II  isotypes. 
Eur.J. Immunol. 19:2171-2174. 
7.  Herman,  A.,  G.  Croteau,  R.-P.  Sekaly, J.  Kappler, and  P. 
Marrack. 1990. HLA-DR alleles differ in their ability to present 
staphylococcal  enterotoxins to T  cells. J.  Exp.  Med. 172:709- 
717. 
8.  Mollick, J.A.,  M.  Chintagumpala,  R.G.  Cook,  and  R.P. 
Rich.  1991.  Staphylococcal exotoxin activation of T  cells. 
Role of exotoxin-MHC class II binding affinity and class II 
isotype.J, Immunol. 146:463-468. 
9.  Swaminathan,  S.,  W. Furey, J.  Pletcher, and M,  Sax.  1992. 
Crystal structure of staphylococcal enterotoxin B, a superan- 
tigen. Nature (Lond.) 359:801-806. 
10. Acharya, K.R., E.F. Passalacqua,  E.Y. Jones, K. Harlos, D.I. 
Stuart, R.D. Brehm, and H.S. Trantor. 1994.  Structural basis 
of superantigen action inferred from crystal structure of toxic- 
shock syndrome toxin-1. Nature (Lond.). 367:94-97. 
11. Jardetzky, T.S., J.H. Brown, J.C. Gorga, L.J. Stern, R.G. Ur- 
ban,  Y.  Chi,  C.  Stauffacher,  J.L.  Strominger,  and  D.C. 
Wiley. 1994. Three-dimensional structure of a human class II 
histocompatibility molecule  complexed  with  superantigen. 
Nature (Lond.). 368:711-718. 
12. Kim, J., R.G. Urban, J.L. Strominger, and D.C. Wiley. 1994. 
Toxic shock syndrome toxin-1 complexed with a class II ma- 
jor histocompatibility molecule  HLA-DR1.  Science (Wash. 
DC). 266:1870-1874. 
13. Scholl, P.R., A. Diez, and R.S. Geha.  1990.  Staphylococcal 
enterotoxin B and toxic shock syndrome toxin-1 bind to dis- 
tinct sites on HLA-DR and HLA-DQ molecules. J. ImmunoL 
143:2583-2588. 
14. Chintagumpala, M.M., J.A. MoUick, and R.R.  Rich.  1991. 
Staphylococcal toxins bind to different sites on HLA-DR. J. 
ImmunoL 147:3876--3881. 
15. Thibodeau, J.,  I.  Cloutier, P.M.  Lavoie, N.  Labrecque, W. 
Mourad,  T.  Jardetzky,  and  R.P.  Sekaly.  1994.  Subsets  of 
1091  Wen et al. 
HLA-DR1 molecules defined by SEB and TSST-1 binding. 
Science (Wash. DC). 266:1874-1878. 
16. Cole, G.A., J.M. Katz, T.L. Hogg, K.W. Ryan, A. Portner, 
and D.L. Woodland. 1994. Analysis of the primary T cell re- 
sponse to Sendai virus infection in C57BL/6 mice: CD4 + T 
cel/recognition is directed predominantly to the hemaggluti- 
nin-neuraminidase glycoprotein.  J.  Virol. 68:6863-6870. 
17. Allen, P.M., D.J. McKean, B.N. Beck, J. Sheffield, and L.H. 
Glimcher. 1985.  Direct evidence that a class II molecule and 
a simple globular protein generate multiple determinants. J. 
Exp. Med.  162:1264-1274. 
18. Allen, P.M.,  G.R.  Matsueda, E.  Haber, and E.R.  Unanue. 
1985.  Specificity of the T-cell receptor: two different deter- 
minants are generated by the same peptide and the I-Ak mol- 
ecule.J. ImmunoL 135:368-373. 
19. Ehrich, E.W., B. Devaux, E.P. Rock, J.L. Jorgensen, M.M. 
Davis, and Y. Chien.  1993.  T  cell receptor interaction with 
peptide/major histocompatibility complex  (MHC)  and  su- 
perantigen/MHC  ligands is  dominated by antigen. J.  Exp. 
Med. 178:713-722. 
20. Woodland, D.L.,  H.P.  Smith,  S.  Surman,  P.  Le,  R.  Wen, 
and M.A.  Blackman.  1993.  Major histocompatibility com- 
plex--specific  recognition of  Mls-I is mediated by multiple el- 
ements of the T  cell receptor. J, Exp. Med.  177:433--442. 
21. Surman,  S.,  A.M.  Deckhut,  M.A.  Blackman,  and  D.L. 
Woodland. 1994. MHC-specific recognition of a bacterial su- 
perantigen by weakly reactive T cells._]. Immunol.  152:4893-- 
4902. 
22. Deckhut,  A.M.,  Y.-h.  Chien,  M,A.  Blackman,  and  D.L. 
Woodland.  1994.  Evidence for a functional interaction be- 
tween  the  13  chain  of Major Histocompatibility  Complex 
class II and the T  cell receptor ot chain during recognition of 
a bacterial superantigen.J. Exp. Med.  180:1931-1935. 
23. Ronchese,  F.,  M.A.  Brown,  and  R.N.  Germain.  1987. 
Structure-function analysis of  the Abm12 beta mutation using 
site directed mutagenesis and DNA-mediated gene transfer.J. 
Immunol. 139:629--638. 
24. Cole,  G.A.,  T.  Tao,  T.L.  Hogg,  K.W.  Ryan,  and  D.L. 
Woodland. 1995. Binding motifs predict major histocompat- 
ibility complex class II-restricted epitopes in the Sendai virus 
M  protein.J.  Virol. 69:8057-8060. 
25. Masewicz, S., J.A. Ledbetter, P.  Martin, E. Mickelson, J.A. 
Hansen,  and  N.  Odum.  1993.  Inhibition of allostimulated 
HLA-DQ and DP-specific T  cells by staphylococcal entero- 
toxin A. Hum. Immunol. 36:142-148. 
26. Dowd, J.E., R.N. Jenkins, and D.R.  Karp.  1995.  Inhibition 
of antigen-specific T  cell activation by  Staphylococcal en- 
terotoxins.J. Immunol. 154:1024-1031. 
27. Vignali, D.A.A., andJ.L. Strominger. 1994. Amino acid resi- 
dues that flank core peptide epitopes and the extracellular do- 
mains of CD4 modulate differential signaling through the T 
cell receptor.J. Exp. Med.  179:1945-1956. 
28.  Cerundolo,  V.,  J.  Alexander,  K.  Anderson,  C.  Lamb,  P. 
Cresswell, A. McMichael, F. Gotch, and A. Townsend. 1990. 
Presentation of viral antigen controlled by a gene in the ma- jot histocompatibility complex. Nature (Lond.). 345:449-452. 
29. Weber, D.A., N.C. Terrell, Y. Zhang, G. Strindberg,  J. Mar- 
tin, A. Rudensky, and N.S. Braunstein.  1995.  Requirement 
for peptide in alloreactive  CD4  + T cell recognition of class II 
MHC molecules.J. Immunol. 154:5153-5164. 
30. Riberdy, J.M., J.R_. Newcomb, M.J.  Surman, J.A. Barbosa, 
and P.  Cresswell.  1992.  HLA-DI~ molecules from an anti- 
gen-processing mutant cell line  are associated with invariant 
chain peptides.  Nature (Lond.). 360:474-476. 
31. Sette,  A., S.  Ceman, K.T.  Kubo, K.  Sakaguchi,  E.  Apella, 
D,F. Hunt, T.A. Davis, H. Michel, J. Shabanowitz, R. Rud- 
ersdorf, et al. 1992. Invariant chain peptides in most HLA-DK 
molecules  of an  antigen-processing  mutant.  Science (Wash. 
DC). 258:1801-1804. 
32. Fling,  S.P.,  B.  Arp,  and D.  Pious.  1994.  HLA-DMA and 
-DMB genes are required for MHC class II/peptide complex 
formation  in  antigen  presenting  cells. Nature  (Lond.). 368: 
554-558. 
33. Morris,  P., J.  Shaman, M. Attaya,  M. Amaya, S. Goodman, 
C. Bergman, J.J. Monaco, and E. MeUins. 1994. An essential 
role for HLA-DM in antigen presentation by class II major 
histocompatibility molecules.  Nature (Lond.). 368:551-554. 
34. Hudson,  K.K.,  K.E.  Tiedemann,  I~.G.  Urban,  S.C.  Lowe, 
J.L.  Strominger,  and J.D.  Fraser.  1995.  Staphylococcal en- 
terotoxin A has two competitive binding sites on major his- 
tocompatibility complex class II.J. Exp. Med. 182:711-720. 
35. Kozono, H., D. Parker, J. White, P. Marrack, andJ. Kappler. 
1995.  Multiple  binding sites for bacterial  superantigens  on 
soluble class I1 molecules.  Immunity. 3:187-196. 
36. Wen, R., M.A. Blackman, and D.L. Woodland. 1995. Vari- 
able influence of MHC polymorphism on the recognition of 
bacterial  superantigens  by  T  cells. J.  Immunol. 155:1884- 
1892. 
37. Yagi, J., T. Uchiyama, and C.A. Janeway, Jr.  1994.  Stimula- 
tor cell type influences  the response  of T  cells to Staphylo- 
coccal enterotoxins.J.  Immunol. 152:1154-1162. 
38. Sun, D., D.L. Woodland, C. Coleclough, U. Wendling, and 
K.  Keske.  1995.  An MHC  class lI-expressing T  cell  clone 
presenting conventional antigen lacks the ability to present bac- 
terial superantigen.  Int. Immunol. 7:1079-1085. 
39. Labrecque, N., J. Thibodeau, W. Mourad, and K.P. Sekaly. 
1994. T cell receptor-major histocompatibility complex class 
II interaction is required for the T  cell response  to bacterial 
superantigens.J.  Exp. Mecl. 180:1921-1929. 
40. Germain,  R.N.,  and  L.R.  Hendrix.  1991.  MHC  class  II 
structure,  occupancy and surface  expression  determined by 
post-endoplasmic reticulum antigen binding.  Nature (Lond.). 
353:134-139. 
41. Stebbins,  C.C.,  G.E.  Loss, Jr.,  C.G.  Elias, A.  Chervonsky, 
and A.J. Sant.  1995. The requirement for DM in class ll-re- 
stricted  antigen presentation and SDS-stable  dimer formation 
is allele and species dependent.J. Exp. Med. 181:223-234. 
42. Posnett, D.N. 1993. Do superantigens  play a role in autoim- 
munity? Semin. Immunol. 5:65-72. 
43. Brocke, S., A. Gaur, C. Piercy, A. Gautam, K. Gijbels, C.G. 
Fathman, and L. Steinman.  1993.  Induction of relapsing  pa- 
ralysis in experimental  autoimmune encephalomyelitis  by bac- 
terial superantigen.  Nature (Lond.). 365:642-644. 
44.  Schiffenbauer,  J.,  H.M.  Johnson,  E.J.  Butfilowski,  L. 
Wegrzyn, and J.M.  Soos.  1993.  Staphylococcal enterotoxins 
can reactivate  experimental  allergic  encephalomyelitis.  Proc. 
Natl. Acad. Sci. USA. 90:8543--8546. 
45. Gaur,  A.,  G.  Fathman,  L.  Steinman,  and S.  Brocke.  1993. 
SEB induced anergy: modulation of immune response  to T 
cell determinants of myoglobin and myelin basic protein. J. 
bnmunot. 150:3062-3069. 
46. Perkins,  D.L., Y. Wang, S.S. Ho, G.K. Wiens, J.G. Seidman, 
and l.J. Rimm. 1993. Superantigen-induced peripheral  toler- 
ance  inhibits  T  cell  responses  to immunogenic peptides  in 
TCK  (beta-chain)  transgenic  mice. J.  Immunol. 150:4284- 
4291. 
47. McCormack, J.E., J. Kappler,  and P. Marrack.  1994. Stimula- 
tion with specific  antigen  can block superantigen-mediated 
deletion  of T  cells in vivo. Proc. Natl.  Acad. Sci. USA.  91: 
2086-2090. 
1092  Peptides Control Bacterial Superantigen  Presentation  to T Cells 